Fc epsilon RI alpha

Fc epsilon RI alpha

Fc epsilon RI alpha Overview

Molecule Name
IgE Fc receptor, alpha-subunit
Synonyms
FCER1A,FCE1A,FcERI
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs1
Highest Development StageApproved
Target Synonym
Fc Fragment Of IgE, High Affinity I, Receptor For; Alpha Polypeptide,FCE1A,IgE Fc receptor subunit alpha,Fc-epsilon RI-alpha,FCER1A,Fc Fragment Of IgE Receptor Ia,Fc Fragment Of IgE, High Affinity I, Receptor For,Alpha Polypeptide,Fc Epsilon Receptor Ia,FcERI,Immunoglobulin E Receptor, High-Affinity, Of Mast Cells, Alpha Polypeptide,High Affinity Immunoglobulin Epsilon Receptor Alpha-Subunit,High Affinity Immunoglobulin Epsilon Receptor Subunit Alpha,Fc IgE Receptor, Alpha Polypeptide,Fc Epsilon RI Alpha-Chain,FCER1
Background
Fc epsilon RI alpha (FcεRIα) is the α-chain of the high-affinity IgE receptor (FcεRI), a critical mediator of type I hypersensitivity. As a transmembrane glycoprotein in the immunoglobulin superfamily, its extracellular domain specifically binds the Fc region of IgE. Mainly expressed on mast cells and basophils, FcεRIα cross-linking (by IgE-allergen complexes) triggers cell degranulation, releasing histamine and proinflammatory mediators—driving allergies, asthma, and anaphylaxis. It also participates in immune surveillance. Owing to its central role in allergic responses, FcεRIα is a key therapeutic target for anti-allergy agents.

Fc epsilon RI alpha Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LesigerceptYH-35324; GI-301Phase 2 ClinicalYuhan Corp
Chronic Urticaria; Hypersensitivity; Immune System Diseases; Urinary Tract Infections; Urticaria
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Benzylpenicilloyl PolylysineApprovedAllerquest LlcPre-penUnited StatesAnaphylaxis; Diagnostic agentsAllerquest Inc1974-07-25
Anaphylaxis; Diagnostic agents
Details